Literature DB >> 9467562

Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine.

I Schuffenecker1, M Virally-Monod, R Brohet, D Goldgar, B Conte-Devolx, L Leclerc, O Chabre, A Boneu, J Caron, C Houdent, E Modigliani, V Rohmer, M Schlumberger, C Eng, P J Guillausseau, G M Lenoir.   

Abstract

Germline mutations of the RET proto-oncogene are responsible for multiple endocrine neoplasia type 2, including multiple endocrine type 2A (MEN 2A), type 2B (MEN 2B), and familial medullary thyroid carcinoma. The relationship between specific mutations and syndromic features has been established. In particular, the risk for pheochromocytoma and hyperparathyroidism (HPT) in MEN 2A patients is clearly associated with the presence of the RET mutation at a specific position, i.e. at codon 634. Also, a correlation between a specific mutation, C634R, and the development of HPT has been suggested but is still controversial. To further investigate the relationship between specific mutations of codon 634 and the development of HPT, we studied a population of 188 individuals, carrying mutations at codon 634, namely C634R (65 patients belonging to 10 families), C634Y (80 patients belonging to 11 families), or the less frequent codon 634 mutations [i.e. C634S, C634F, C634G, or C634W (43 patients belonging to 9 families)]. In this series of patients, we defined an overall HPT prevalence of 19.1% and found that this prevalence did not vary significantly, with respect to the nature of the mutation. However, irrespective of the particular mutation, the prevalence of HPT showed a high interfamilial variability. The statistical model that best fitted with the observed data was in favor of the heterogeneity of the risk for HPT, with 40% of the families showing an HPT risk of 34% and 60% of the families showing an HPT risk of 9%. In addition, our study clearly demonstrated that HPT could be an early component of the disease and provided the first estimate of age-specific and mutation-specific HPT penetrance in individuals with mutations of codon 634 of the RET proto-oncogene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467562     DOI: 10.1210/jcem.83.2.4529

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

Review 1.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Probability of Positive Genetic Testing Results in Patients with Family History of Primary Hyperparathyroidism.

Authors:  Mustapha El Lakis; Pavel Nockel; Apostolos Gaitanidis; Bin Guan; Sunita Agarwal; James Welch; William F Simonds; Lee Weinstein; Stephen Marx; Naris Nilubol; Dhaval Patel; Roxanne Merkel; Amit Tirosh; Electron Kebebew
Journal:  J Am Coll Surg       Date:  2018-03-02       Impact factor: 6.113

Review 3.  Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.

Authors:  Stephen J Marx; David Goltzman
Journal:  J Bone Miner Res       Date:  2018-12-10       Impact factor: 6.741

4.  [Prophylactic parathyroidectomy for familial parathyroid carcinoma].

Authors:  O Gimm; K Lorenz; P Nguyen Thanh; U Schneyer; M Bloching; V M Howell; D J Marsh; B T Teh; U Krause; H Dralle
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

Review 5.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 6.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

Review 7.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

Review 8.  Update multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

9.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

Review 10.  Medullary thyroid carcinoma and multiple endocrine neoplasia type 2.

Authors:  Hiroshi Takami
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.